Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)

NCT06774027 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT06774027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)
Lead sponsor
University of California, San Francisco
Phase
Observational
Overall status
Recruiting
Start date
October 8, 2025
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 negative breast carcinoma, her2-negative breast cancer, hr+ her2 breast cancer, metastatic breast cancer, metastatic triple negative breast cancers, metastatic triple-negative breast carcinoma